- Home
- SLXN
SLXN
BIOMOTION SCIENCES
as 11-15-2024 4:00pm EST
Stocks
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
| Founded: | 2008 | Country: | Israel |
| Employees: | N/A | City: | MODIIN-MACCABIM-REUT |
| Market Cap: | 3.0M | IPO Year: | N/A |
| Target Price: | $1.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.21 - $13.56 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BIOMOTION SCIENCES News
SLXN Breaking Stock News: Dive into SLXN Ticker-Specific Updates for Smart Investing
ACCESSWIRE
4 days ago
Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
ACCESSWIRE
a month ago
Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit
Business Wire
2 months ago
Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
Business Wire
2 months ago
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer
Business Wire
2 months ago
PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers
GlobeNewswire
2 months ago
Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference
GlobeNewswire
3 months ago
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination
Compare SLXN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLXN BIOMOTION SCIENCES - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.